STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 1, 2007, Pages 288-297

  Greene, Lisa M ^a   Kelly, Liam ^a   Onnis, Valeria ^a   Campiani, Giuseppe ^b   Lawler, Mark ^c   Williams, D Clive ^a   Zisterer, Daniela M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF SIENA   (Italy)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOCODAZOLE; PACLITAXEL; PROPIDIUM IODIDE; PROTEIN BCL XL; PROTEIN MCL 1; PYRROLO 1,5 BENZOXAZEPINE 6; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MICROTUBULES; MONOCYTES; NEOPLASM PROTEINS; OXAZEPINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; PYRROLES;

EID: 33947409844     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.116640     Document Type: Article

References (41)

1. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, et al. (2005) Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105:3303-3311.
2. Apte SM, Fan D, Killion JJ, and Fidler IJ (2004) Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10:897-908.
3. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, and Sette A (1995) Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85:2680-2684.
4. Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Ciani SM, Greco G, Novellino E, Williams DC, Zisterer DM, et al. (1996) Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheraltype" benzodiazepine receptor ligands. J Med Chem 39:3435-3450.
5. Casenghi M, Mangiacasale R, Tuynder M, Caillet-Fauquet P, Elhajouji A, Lavia P, Mousset S, Kirsch-Volders M, and Cundari E (1999) p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells. Exp Cell Res 250:339-350.
6. Cotter TG (1995) BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Leuk Lymphoma 18:231-236.
7. de Groot RP, Raaijmakers JA, Lammers JW, and Koenderman L (2000) STAT5-dependent cyclin D1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 3:299-305.
8. Druker BJ (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91:1-30.
9. Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP Jr, and Wei S (2001) Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocytemacrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol 166:7486-7495.
10. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, and Pellman D (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature (Lond) 437:1043-1047.
11. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, et al. (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641-1650.
12. Greene LM, Fleeton M, Mulligan J, Gowda C, Sheahan BJ, Atkins GJ, Campiani G, Nacci V, Lawler M, Williams DC, et al. (2005) The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status, and inhibits breast tumour growth in vivo. Oncol Rep 5:1357-1363.
13. Hong FD, Chen J, Donovan S, Schneider N, and Nisen PD (1999) Taxol, vincristine or nocodazole induces lethality in G1-checkpoint-defective human astrocytoma U373MG cells by triggering hyperploid progression. Carcinogenesis 20:1161-1168.
14. Hoover RR, Gerlach MJ, Koh EY, and Daley GQ (2001) Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 20:5826-5835.
15. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, and Furukawa Y (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007.
16. Khan SH and Wahl GM (1998) p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 58:396-401.
17. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, and Toge T (2005) Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103:1800-1809.
18. Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, Fan D, Killion JJ, and Fidler IJ (2004) Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 64:4201-4208.
19. Lanni JS and Jacks T (1998) Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18:1055-1064.
20. Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, and Price JE (2005) Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 11:306-314.
21. Martiat P, Lewalle P, Taj AS, Philippe M, Larondelle Y, Vaerman JL, Wildmann C, Goldman JM, and Michaux JL (1993) Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines. Blood 81:502-509.
22. Mazzacurati L, Pattacini L, Brusa G, Mancini M, Benvenuti M, Barbieri E, Martinelli G, Baccarani M, Greenberger JS, and Santucci MA (2004) Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. Hematol J 5:168-177.
23. McGee MM, Campiani G, Ramunno A, Fattorusso C, Nacci V, Lawler M, Williams DC, and Zisterer DM (2001) Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl. J Pharmacol Exp Ther 296:31-40.
24. McGee MM, Campiani G, Ramunno A, Nacci V, Lawler M, Williams DC, and Zisterer DM (2002) Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. J Biol Chem 277:18383-18389.
25. McGee MM, Greene LM, Ledwidge S, Campiani G, Nacci V, Lawler M, Williams DC, and Zisterer DM (2004) Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1- d] (1,5)-benzoxazepine (PBOX-6) in leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL. J Pharmacol Exp Ther 310:1084-1095.
26. Minn AJ, Boise LH, and Thompson CB (1996) Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev 10:2621-2631.
27. Motwani M, Li X, and Schwartz GK (2000) Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Clin Cancer Res 6:924-932.
28. Mulligan J, Greene LM, Cloonan S, McGee MM, Onnis V, Campiani G, Nacci V, Lawler M, Williams DC, and Zisterer DM (2006) Identification of tubulin as the molecular target of pro-apoptotic pyrrolo-1,5-benzoxazepines. Mol Pharmacol 70:60-70.
29. Nimmanapalli R and Bhalla K (2002) Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene 21:8584-8590.
30. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, and Bhalla K (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101:3236-3239.
31. Nishimura N, Furukawa Y, Sutheesophon K, Nakamura M, Kishi K, Okuda K, Sato Y, and Kano Y (2003) Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. Oncogene 22: 4074-4082.
32. Roberts JR, Allison DC, Donehower RC, and Rowinsky EK (1990) Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 50:710-716.
33. Sanchez-Garcia I and Martin-Zanca D (1997) Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol 267:225-228.
34. Sattler M and Salgia R (1997) Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 8:63-79.
35. Skorski T (2002) BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21:8591-8604.
36. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, and McCubrey JA (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218.
37. Stewart ZA, Leach SD, and Pietenpol JA (1999) p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol 19:205-215.
38. Verdoodt B, Decordier I, Geleyns K, Cunha M, Cundari E, and Kirsch-Volders M (1999) Induction of polyploidy and apoptosis after exposure to high concentrations of the spindle poison nocodazole. Mutagenesis 14:513-520.
39. Yanovich S, Hall RE, and Gewirtz DA (1989) Characterization of a K562 multidrug-resistant cell line. Cancer Res 49:4499-4503.
40. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, and Grant S (2002) Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62:188-199.
41. Zisterer DM, Campiani G, Nacci V, and Williams DC (2000) Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents. J Pharmacol Exp Ther 293:48-59.